ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company specializing in plasma-derived therapeutics. The company's commercial portfolio features FDA-approved intravenous immune globulin (IVIG) products, including ASCENIV and BIVIGAM, as well as NABI-HB, a hepatitis B immune globulin. To support its manufacturing operations, the company operates ADMA BioCenters, a subsidiary network of FDA-approved source plasma collection facilities that provide a reliable supply of human blood plasma. ADMA utilizes proprietary microneutralization assay technology to identify and collect plasma with high titers of neutralizing antibodies. By vertically integrating plasma collection, fractionation, and purification at its dedicated manufacturing facilities, the company maintains strict control over its supply chain while serving hospitals, clinics, and specialty pharmacies.
